Product Description
Aripiprazole is a medication that works in the brain to treat schizophrenia. It is also known as a second generation antipsychotic (SGA) or atypical antipsychotic. Aripiprazole rebalances dopamine and serotonin to improve thinking, mood, and behavior. (Sourced from: https://www.nami.org/About-Mental-Illness/Treatments/Mental-Health-Medications/Types-of-Medication/Aripiprazole-(Abilify))
Mechanisms of Action: D2 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Bipolar Disorder | Schizophrenia | Bipolar Disorder | Depressive Disorder | Depressive Disorder, Major | Bipolar Disorder | Depressive Disorder | Depressive Disorder, Major | Autism Spectrum Disorder | Tic Disorders | Schizophrenia
Known Adverse Events: Pain Unspecified | Schizophrenia | Bipolar Disorder | Tremor | Insomnia | Constipation | Depressive Disorder | Depressive Disorder, Major | Autism Spectrum Disorder | Tic Disorders | Dizziness | Headache | Lethargy | Nasopharyngitis | Pharyngitis
Company: Otsuka
Company Location: NEW YORK NY 10271
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Korea, New Zealand, Unknown Location
Active Clinical Trial Count: 7
Highest Development Phases
Phase 3: Bipolar Disorder|Rett Syndrome|Schizophrenia|Tourette Syndrome
Phase 2: Dermatitis, Atopic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| APOLLO | P3 |
Recruiting |
Bipolar Disorder |
2025-11-01 |
|
| 2006-7041-83/hah | P2 |
Not yet recruiting |
Dermatitis, Atopic |
2023-07-20 |
|
| CTR20201480 | P1 |
Not yet recruiting |
Schizophrenia |
None |
|
| CTR20190492 | P3 |
Recruiting |
Schizophrenia |
None |